Selected research
Industry Research
Immune Checkpoint Inhibitors for Cancer Industry Research Report 2026
Market perspective
The global Immune Checkpoint Inhibitors for Cancer market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Immune Checkpoint Inhibitors for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Immune Checkpoint Inhibitors for Cancer is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Immune Checkpoint Inhibitors for Cancer is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Immune Checkpoint Inhibitors for Cancer include Innovent Biologics, Merck, Roche, Pfizer, Zydus, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Immune Checkpoint Inhibitors for Cancer market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Immune Checkpoint Inhibitors for Cancer Market by Company
Innovent Biologics
Merck
Roche
Pfizer
Zydus
Regeneron Pharmaceuticals
Bristol Myers Squibb
AstraZeneca
Immune Checkpoint Inhibitors for Cancer Segment by Type
CTLA-4 Inhibitors
PD-1 Inhibitors
PD-L1 Inhibitors
Immune Checkpoint Inhibitors for Cancer Segment by Application
Gastric Cancer
Squamous Cell Skin Cancer
Melanoma
Non-small Cell Lung Cancer
Others
Immune Checkpoint Inhibitors for Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Inhibitors for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Inhibitors for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Inhibitors for Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Immune Checkpoint Inhibitors for Cancer manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Immune Checkpoint Inhibitors for Cancer by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Immune Checkpoint Inhibitors for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CTLA-4 Inhibitors
- PD-1 Inhibitors
- PD-L1 Inhibitors
Applications
- Gastric Cancer
- Squamous Cell Skin Cancer
- Melanoma
- Non-small Cell Lung Cancer
- Others
Companies covered
- Innovent Biologics
- Merck
- Roche
- Pfizer
- Zydus
- Regeneron Pharmaceuticals
- Bristol Myers Squibb
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Immune Checkpoint Inhibitors for Cancer Market Size (2021-2032)
- 2.2.2 Global Immune Checkpoint Inhibitors for Cancer Sales (2021-2032)
- 2.2.3 Global Immune Checkpoint Inhibitors for Cancer Market Average Price (2021-2032)
- 2.3 Immune Checkpoint Inhibitors for Cancer by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CTLA-4 Inhibitors
- 2.3.3 PD-1 Inhibitors
- 2.3.4 PD-L1 Inhibitors
- 2.4 Immune Checkpoint Inhibitors for Cancer by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastric Cancer
- 2.4.3 Squamous Cell Skin Cancer
- 2.4.4 Melanoma
- 2.4.5 Non-small Cell Lung Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Immune Checkpoint Inhibitors for Cancer Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Immune Checkpoint Inhibitors for Cancer Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Immune Checkpoint Inhibitors for Cancer Revenue of Manufacturers (2021-2026)
- 3.4 Global Immune Checkpoint Inhibitors for Cancer Average Price by Manufacturers (2021-2026)
- 3.5 Global Immune Checkpoint Inhibitors for Cancer Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Immune Checkpoint Inhibitors for Cancer, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Immune Checkpoint Inhibitors for Cancer, Product Type & Application
- 3.8 Global Manufacturers of Immune Checkpoint Inhibitors for Cancer, Established Date
- 3.9 Global Immune Checkpoint Inhibitors for Cancer Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Innovent Biologics
- 4.1.1 Innovent Biologics Company Information
- 4.1.2 Innovent Biologics Business Overview
- 4.1.3 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Innovent Biologics Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.1.5 Innovent Biologics Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Zydus
- 4.5.1 Zydus Company Information
- 4.5.2 Zydus Business Overview
- 4.5.3 Zydus Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zydus Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.5.5 Zydus Recent Developments
- 4.6 Regeneron Pharmaceuticals
- 4.6.1 Regeneron Pharmaceuticals Company Information
- 4.6.2 Regeneron Pharmaceuticals Business Overview
- 4.6.3 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Regeneron Pharmaceuticals Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.6.5 Regeneron Pharmaceuticals Recent Developments
- 4.7 Bristol Myers Squibb
- 4.7.1 Bristol Myers Squibb Company Information
- 4.7.2 Bristol Myers Squibb Business Overview
- 4.7.3 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bristol Myers Squibb Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.7.5 Bristol Myers Squibb Recent Developments
- 4.8 AstraZeneca
- 4.8.1 AstraZeneca Company Information
- 4.8.2 AstraZeneca Business Overview
- 4.8.3 AstraZeneca Immune Checkpoint Inhibitors for Cancer Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca Immune Checkpoint Inhibitors for Cancer Product Portfolio
- 4.8.5 AstraZeneca Recent Developments
5 Global Immune Checkpoint Inhibitors for Cancer Market Scenario by Region
- 5.1 Global Immune Checkpoint Inhibitors for Cancer Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Region: 2021-2032
- 5.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Region: 2021-2026
- 5.2.2 Global Immune Checkpoint Inhibitors for Cancer Sales by Region: 2027-2032
- 5.3 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region: 2021-2032
- 5.3.1 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region: 2021-2026
- 5.3.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Region: 2027-2032
- 5.4 North America Immune Checkpoint Inhibitors for Cancer Market Facts & Figures by Country
- 5.4.1 North America Immune Checkpoint Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
- 5.4.3 North America Immune Checkpoint Inhibitors for Cancer Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Immune Checkpoint Inhibitors for Cancer Market Facts & Figures by Country
- 5.5.1 Europe Immune Checkpoint Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
- 5.5.3 Europe Immune Checkpoint Inhibitors for Cancer Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Immune Checkpoint Inhibitors for Cancer Market Facts & Figures by Country
- 5.6.1 Asia Pacific Immune Checkpoint Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Immune Checkpoint Inhibitors for Cancer Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Immune Checkpoint Inhibitors for Cancer Market Facts & Figures by Country
- 5.7.1 South America Immune Checkpoint Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
- 5.7.3 South America Immune Checkpoint Inhibitors for Cancer Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Immune Checkpoint Inhibitors for Cancer Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021-2032)
- 6.1.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Type (2021-2032)
- 6.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Type (2021-2032)
- 6.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Type (2021-2032)
- 6.3 Global Immune Checkpoint Inhibitors for Cancer Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021-2032)
- 7.1.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Immune Checkpoint Inhibitors for Cancer Sales Market Share by Application (2021-2032)
- 7.2 Global Immune Checkpoint Inhibitors for Cancer Revenue by Application (2021-2032)
- 7.2.1 Global Immune Checkpoint Inhibitors for Cancer Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Immune Checkpoint Inhibitors for Cancer Revenue Market Share by Application (2021-2032)
- 7.3 Global Immune Checkpoint Inhibitors for Cancer Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Immune Checkpoint Inhibitors for Cancer Value Chain Analysis
- 8.1.1 Immune Checkpoint Inhibitors for Cancer Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Immune Checkpoint Inhibitors for Cancer Production Mode & Process
- 8.2 Immune Checkpoint Inhibitors for Cancer Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Immune Checkpoint Inhibitors for Cancer Distributors
- 8.2.3 Immune Checkpoint Inhibitors for Cancer Customers
9 Global Immune Checkpoint Inhibitors for Cancer Analyzing Market Dynamics
- 9.1 Immune Checkpoint Inhibitors for Cancer Industry Trends
- 9.2 Immune Checkpoint Inhibitors for Cancer Industry Drivers
- 9.3 Immune Checkpoint Inhibitors for Cancer Industry Opportunities and Challenges
- 9.4 Immune Checkpoint Inhibitors for Cancer Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst